In a meta-analysis of RCTs, the pooled analysis suggested a significant increase in % changes of adiponectin (0.75; 95% CI, 0.40 to 1.09; p < 0.0001) among patients with metabolic syndrome randomized to receive telmisartan or control therapy [185]. Here, ADIPOQ is linked to metabolic syndrome.